FDA approved first gene therapies to treat patients with sickle cell disease
On Dec. 8, 2023, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing…
Vertex and CRISPR Therapeutics announced authorization of first CRISPR/Cas9 gene-edited therapy by UK MHRA for treatment of Sickle Cell Disease
On Nov. 16, 2023, Vertex and CRISPR Therapeutics announced that the United Kingdom (U.K.) Medicines and Healthcare products…
First patent application granted for CRISPR-Cas9 gene editing in all environments
On May 25, 2012, Drs. Jennifer Doudna, Emanulle Charpentier, Martin Jinek of UC Berkeley and Krzystof Chylinski of…